Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-24

Study Completion Date

2022-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies. Giving low-doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) before the transplant may help increase this effect.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT02566304

Acute Myeloid Leukemia Acute Myeloid Leukemia in Remission Aplastic Anemia +12 more

COMPLETED PHASE2

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

NCT01384513

Adult Acute Lymphoblastic Leukemia in Remission Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities +44 more

COMPLETED PHASE2

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

NCT00049504

Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remission Adult Acute Myeloid Leukemia in Remission +94 more

COMPLETED PHASE2

A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

NCT03032783

Hematopoietic and Lymphoid Cell Neoplasm

ACTIVE_NOT_RECRUITING PHASE2

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT00104975

Chronic Myeloproliferative Disorders Leukemia Lymphoma +2 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC regimen.

SECONDARY OBJECTIVES:

I. To assess the 100 day regimen-related mortality (RRM) in patients undergoing HSCT on this treatment protocol.

II. To determine the incidence and severity of graft-versus-host disease (GVHD) in patients undergoing treatment on this regimen.

III. To evaluate engraftment rates and lymphoid reconstitution in patients treated on this trial.

IV. To assess overall survival at 1 and 3 years past HSCT in patients treated on this trial.

OUTLINE:

REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate intravenously (IV) on days -15 to -12, busulfan IV on days -14 to -13, donor lymphocyte infusion (DLI) on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo total-body irradiation (TBI) on day -10.

TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplant (PBSCT) on day 0.

GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV twice daily (BID) on days -1 to 28.

After completion of study treatment, patients are followed up periodically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myeloid Leukemia With FLT3/ITD Mutation Acute Myeloid Leukemia With Gene Mutations Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214 Aplastic Anemia Chronic Lymphocytic Leukemia Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Follicular Lymphoma Hodgkin Lymphoma Myelodysplastic Syndrome Myelofibrosis Myeloid Leukemia Non-Hodgkin Lymphoma Plasma Cell Myeloma Polycythemia Vera Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (RIC and allogeneic PBSCT)

REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.

TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.

GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28

Group Type EXPERIMENTAL

Fludarabine phosphate

Intervention Type DRUG

Given IV

Busulfan

Intervention Type DRUG

Given IV

Total-Body Irradiation

Intervention Type RADIATION

Undergo TBI

Therapeutic Allogeneic Lymphocytes

Intervention Type BIOLOGICAL

Undergo DLI

Cyclophosphamide

Intervention Type DRUG

Given IV

Allogeneic Hematopoietic Stem Cell Transplantation

Intervention Type PROCEDURE

Undergo allogeneic PBSCT

Peripheral Blood Stem Cell Transplantation

Intervention Type PROCEDURE

Undergo allogeneic PBSCT

Tacrolimus

Intervention Type DRUG

Given IV

Mycophenolate Mofetil

Intervention Type DRUG

Given IV

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fludarabine phosphate

Given IV

Intervention Type DRUG

Busulfan

Given IV

Intervention Type DRUG

Total-Body Irradiation

Undergo TBI

Intervention Type RADIATION

Therapeutic Allogeneic Lymphocytes

Undergo DLI

Intervention Type BIOLOGICAL

Cyclophosphamide

Given IV

Intervention Type DRUG

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSCT

Intervention Type PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSCT

Intervention Type PROCEDURE

Tacrolimus

Given IV

Intervention Type DRUG

Mycophenolate Mofetil

Given IV

Intervention Type DRUG

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

2-F-ara-AMP 75607-67-9 9H-Purin-6-amine 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)- 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl) Beneflur Fludara Fludarabine-5'-Monophosphate SH T 586 1, 4-Bis[methanesulfonoxy]butane 1,4-Bis(methanesulfonoxy)butane 1,4-Bitanediol Dimethanesulfonate Esters 1,4-Butanediol Dimethylsulfonate 1,4-Di(methanesulfonyloxy)butane 1,4-Di(methylsulfonyloxy)butane 55-98-1 BUS Bussulfam Busulfanum Busulfex Busulphan CB 2041 CB-2041 Glyzophrol GT 41 GT-41 Joacamine Methanesulfonic Acid Tetramethylene Ester Methanesulfonic acid tetramethylene ester Mielucin Misulban Misulfan Mitosan Myeleukon Myeloleukon Myelosan Mylecytan Myleran Sulfabutin Tetramethylene Bis(methanesulfonate) Tetramethylene bis[methanesulfonate] WR-19508 TBI SCT_TBI TOTAL BODY IRRADIATION Whole Body Whole Body Irradiation Whole-Body Irradiation Allogeneic Lymphocytes (-)-Cyclophosphamide 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate 2-[bis(b-chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane-2-oxide monohydrate 2-[di(chloroethyl)amino]-1-oxa-3-aza-2-phosphacyclohexane 2-oxide monohydrate 2H-1,3,2-Oxazaphosphorine 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate 6055-19-2 bis(2-chloroethyl)phosphamide cyclic propanolamide ester monohydrate Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester monohydrate Carloxan Ciclofosfamida Ciclofosfamide Cicloxal Clafen Claphene CP monohydrate CTX CYCLO-cell Cycloblastin Cycloblastine Cyclophospham Cyclophosphamid monohydrate Cyclophosphamide Monohydrate Cyclophosphamidum Cyclophosphan Cyclophosphane Cyclophosphanum Cyclostin Cyclostine Cytophosphan Cytophosphane Cytoxan Fosfaseron Genoxal Genuxal Ledoxina Mitoxan N,N-bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)phosphorodiamidic acid intramolecular ester monohydrate N,N-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide monohydrate N,N-bis(b-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate N,N-bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide monohydrate N,N-bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide monohydrate Neosar Revimmune Syklofosfamid WR- 138719 Allogeneic Allogeneic Hematopoietic Cell Transplantation allogeneic stem cell transplantation HSC HSCT Stem Cell Transplantation PBPC transplantation PBSCT Peripheral Blood Peripheral Blood Progenitor Cell Transplantation PERIPHERAL BLOOD STEM CELL TRANSPLANT peripheral stem cell support Peripheral Stem Cell Transplant peripheral stem cell transplantation 109581-93-3 FK 506 Fujimycin Hecoria Prograf Protopic 115007-34-6 128794-94-5 Cellcept MMF

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* By definition, patients with hematological malignancies or dyscrasias that require HSCT as part of cure-directed therapy are by definition high-risk and can be treated on this protocol; examples of high risk patients include but are not limited to:

* Acute myeloid leukemia with high risk features as defined by:

* Age greater than or equal to 60
* Secondary acute myeloid leukemia (AML) (prior therapy or hematologic malignancy)
* Normal cytogenetics but fms-related tyrosine kinase 3 (FLT3)/internal tandem duplication (ITD) positive
* Any relapse or primary refractory disease
* Greater than 3 cytogenetic abnormalities or any one of the following cytogenetic abnormalities: -5/del(5q), -7/del(7q), Abn(9q), (11q), (3q), (21q), (17p), t(6;9), t(6;11), t(11;19), +8, del(12p), inv(3), t(10;11), -17, 11q 23
* Any single autosomal monosomy
* Acute lymphoid leukemia in 1st or 2nd morphological remission; ALL with any morphological evidence of disease will not be eligible
* Myelodysplasia (MDS) other than refractory anemia (RA), refractory anemia with rare sideroblasts (RARS), or isolated 5q- syndrome subtypes
* Hodgkin's or Non-Hodgkin's lymphoma in 2nd or greater remission or with persistent disease
* Myeloma with evidence of persistent disease after front-line therapy
* Chronic myeloid leukemia (CML) resistant to signal transducer inhibitor (STI) therapy
* Myelofibrosis and chronic myelomonocytic leukemia (CMML)
* Essential thrombocytopenia or polycythemia vera with current or past evidence of evolution to acute leukemia
* Patients with chronic lymphocytic leukemia (CLL), follicular non-Hodgkin lymphoma (NHL), or other lymphoid malignancies who have highly adverse cytogenetics (such as p53 deletion), are chemo-insensitive, are not responsive to highly effective novel treatments such as chimeric antigen receptor T-lymphocytes (CART) or Ibrutinib, or who have transformed disease
* Any hematological malignancy not cited above which is thought to be high-risk with increased chance of post HSCT relapse
* Any patient who has an aggressive disease that would normally be treated on a myeloablative study, but is prevented from doing so by factors in their past medical history; examples are patients with previous treatment with radiation therapy precluding TBI, or a past history of myeloablative therapy, precluding a 2nd myeloablative regimen
* Patients with aplastic anemia may be treated on this protocol, with outcomes reported descriptively
* Patients must have a related donor who is at least a 2-4/8 antigen mismatch at the human leukocyte antigen (HLA)-A; B; C; DR loci; patients with only a 1 out of 8 mismatch in the GVH direction will be classified in the matched related category
* Left ventricular end diastolic function (LVEF) of \>= 50%
* Diffusion lung capacity of oxygen (DLCO) \>= 50% of predicted corrected for hemoglobin
* Serum bilirubin =\< 1.8
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal
* Creatinine clearance of \>= 60 mL/min
* Patients \< age 60 years must have a Karnofsky performance status (KPS) of \>= 80% and a hematopoietic cell transplant comorbidity index (HCT-CI) score of 5 or less
* Patients aged 60 to 65 years must have a KPS of \>= 80% and an HCT-CI score of 4 or less
* Patients aged 66 to 69 years must have a KPS of 90% and an HCT-CI score of 3 or less
* Patients aged 70 years or more must have a KPS of 90% and an HCT-CI score of 2 or less

\* (Patients with greater than the allowable HCT-CI points for age can be enrolled for trial with approval of the principal investigator \[PI\] and at least 1 co-investigator \[Co-I\] not on the primary care team of the patient) this is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than guideline HCT-CI points; an example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities
* Patients must be willing to use contraception if they have childbearing potential
* Patient or patient's guardian is able to give informed consent

Exclusion Criteria

* Human immunodeficiency virus (HIV) positive
* Active involvement of the central nervous system with malignancy; this can be documented as a normal neurological exam and/or a negative cerebrospinal fluid (CSF) analysis
* Pregnancy
* Patients with life expectancy of =\< 6 months for reasons other than their underlying hematologic/oncologic disorder
* Patients who have received alemtuzumab or ATG within 8 weeks of the transplant admission
* Patients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocol

Eligible Sex

ALL

Accepts Healthy Volunteers

No